Health tech startup uMed has raised £3.7m in new funding for its solution that helps automate processes in running clinical studies.
The latest funding follows a previous raises of £1m in October 2019 from Playfair Capital which continues as an investor in its latest round.
The company now plans to use the investment to grow its platform which automates processes such as patient matching and capturing data from the patient and EHR.
University of Oxford is using the tool to support the RAPTOR-C19 study, part of the national priority CONDOR platform evaluating the use of COVID-19 diagnostics in different settings. RAPTOR-C19 is comparing the accuracy of different rapid tests for Covid-19 among patients in community settings, such as GP surgeries. It has helped digitally target patients for this study, enabling e-consent and the automated capture of outcomes remotely.
Dr Matt Wilson, a former NHS anaesthetist and Medical Officer in the Royal Marines, founded the company, and the platform is now used in 160 primary care sites in the UK, along with two million patients from a large US health system available from early next year.
Dr Wilson says: “Our technology can support healthcare providers in finding appropriate patients to participate in medical research including large scale patient registries which usually demands laborious, manual processes on top of their already complex and heavy workloads.”
“As our technology is uniquely able to reach back compliantly from the Electronic Health Record (EHR) to the patients, the process for building research registries can be heavily automated. It means clinicians can focus on patient care, while patients are given the opportunity to participate in many more studies from home with full transparency over use of their health records.”
Investors in the latest funding round include AlbionVC, Delin Ventures and Playfair Capital and Silicon Valley based 11.2 Capital.
